Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.71 |
| ▸ | CA1 | P00915 | 3/20 | 0.71 |
| ▸ | CA2 | P00918 | 3/20 | 0.71 |
| ▸ | CA9 | Q16790 | 3/20 | 0.71 |
| ▸ | PDE4A | P27815 | 1/20 | 0.63 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.63 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29394932 | 0.97 | CA12 (0.68) | CA12CA1CA2CA9PDE4A | |
| SCHEMBL29394481 | 0.90 | GAA (0.74) | CA12CA1CA2CA9PDE4A | |
| SCHEMBL29392708 | 0.90 | GAA (0.74) | CA12CA1CA2CA9PDE4A | |
| SCHEMBL29395070 | 0.89 | PDE4A (0.60) | CA12CA1CA2CA9PDE4A | |
| SCHEMBL29395562 | 0.89 | PDE4A (0.60) | CA12CA1CA2CA9PDE4A | |
| SCHEMBL29394870 | 0.89 | GAA (0.76) | CA12CA1CA2CA9PDE4A | |
| SCHEMBL29392174 | 0.89 | PDE4A (0.60) | CA12CA1CA2CA9PDE4A | |
| SCHEMBL23533860 | 0.86 | CA12 (0.64) | CA12CA1CA2CA9PDE4A | |
| SCHEMBL29392433 | 0.85 | CA12 (0.70) | CA12CA1CA2CA9PDE4A | |
| SCHEMBL29394845 | 0.85 | PDE4A (0.56) | CA12CA1CA2CA9PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114057650-B | Method for preparing 4, 5-dihydropyridazin-3-one compounds by one-pot method | 温州大学 | 2023-03-28 | — | — | CN | disclosed |
| CN-114057650-A | Method for preparing 4, 5-dihydropyridazin-3-one compounds by one-pot method | 温州大学 | 2022-02-18 | — | — | CN | disclosed |
| US-20060189622-A1 | Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| US-20030225081-A1 | Pyridazinones and triazinones and medicinal use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-12-04 | — | — | US | disclosed |
| EP-1319659-A1 | PYRIDAZINONES AND TRIAZINONES AND MEDICINAL USE THEREOF | Eisai Co., Ltd. (JP) | 2003-06-18 | — | — | EP | disclosed |
| US-4397854-A | INCREASE IN MYOCARDIAL CONTRACTILITY | WARNER-LAMBERT COMPANY (US) | 1983-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225081-A1 | Pyridazinones and triazinones and medicinal use thereof | GRIK1, GRIK3, GRIK2 | CA12 1556/4885CA1 378/4885CA2 424/4885 |
| US-20060189622-A1 | Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations | GRIK3, GRIK1, GRIK2 | CA12 2084/4885CA1 599/4885CA2 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.